Improvement of hematopoietic stem cell transplantation in the targeted therapy era

Di-san junyi daxue xuebao

ZHANG Xi¹  HUANG Ruihao¹ 

[1] State Key Laboratory of Trauma, Burns and Combined Injury, Medical Center of Hematology, PLA Center for Hematology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China;

关键词: allogeneic hematopoietic stem cell transplantation;    hematologic neoplasms;    car-t cell therapy;    targeted therapy;   

DOI  :  10.16016/j.1000-5404.202108154

来源: DOAJ

【 摘 要 】

Hematopoietic stem cell transplantation (HSCT) is one of best ways to treat hematological malignancies. And, allogeneic HSCT has been developing rapidly in our country within recent decades, and accomplished many transplantation schemes and technological systems with Chinese characteristics. Especially, the mature application of haplo-identical HSCT promotes the transplantation into an era of "everyone has a donor". Nowadays, constantly emerged epigenetic regulators, pathway modulators of leukemia genesis and immune cell therapies have provided more options for physician and patients so far in HSCT. In this article, we summarize the application of new drugs in the whole process of allogeneic HSCT (before, during and after transplantation) and related new technologies and new schemes. We consider that the closer combination of new drugs such as targeted drugs and HSCT is an effective measure to further improve the efficacy and safety of allogeneic HSCT. We should organically integrate the existing technologies and new drugs into the best scheme in order to further enhance the efficacy and improve the quality of life of patients. This is a problem that must be focused on in this field in the future.

【 授权许可】

Unknown